Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 101 entries
View as:

The Real-world Clinical Study of Azvudine Tablets in the Treatment of COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT06349655 Org: User:
Start: 12/05/23 End: 03/10/24 Due: 03/10/25

Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT05114941 Org: User:
Start: 01/01/26 End: 12/31/26 Due: 12/31/27

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL

Phase: N/A Priority: Normal
NCT ID: NCT06557161 Org: User:
Start: 03/01/25 End: 12/31/29 Due: 12/31/30

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Phase: N/A Priority: Normal
NCT ID: NCT06559345 Org: User:
Start: 03/17/25 End: 08/31/29 Due: 08/31/30

Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05189184 Org: User:
Start: 03/30/22 End: 03/30/25 Due: 03/30/26

MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT05286957 Org: User:
Start: 06/20/22 End: 06/01/27 Due: 06/01/28

A Clinical Study of Herombopag in Tumors-associated Thrombocytopenia

Phase: N/A Priority: Normal
NCT ID: NCT05350956 Org: User:
Start: 06/01/22 End: 10/30/23 Due: 10/30/24

The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC

Phase: N/A Priority: Normal
NCT ID: NCT03917966 Org: User:
Start: 04/07/20 End: 10/07/24 Due: 10/07/25

Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05812430 Org: User:
Start: 04/10/23 End: 10/10/24 Due: 10/10/25

A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT03736863 Org: User:
Start: 12/05/19 End: 12/30/25 Due: 12/30/26

Mindfulness Yoga and Sexual Functioning

Phase: N/A Priority: Normal
NCT ID: NCT05461534 Org: User:
Start: 08/01/22 End: 08/01/24 Due: 08/01/25

Botulinum Toxin for Trigeminal Neuralgia

Phase: N/A Priority: Normal
NCT ID: NCT03331913 Org: User:
Start: 11/07/17 End: 03/31/19 Due: 03/31/20

An Exploratory Study of Surufatinib Combined With Chidamide and Fulvestrant in HR Positive Unresectable Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05186545 Org: User:
Start: 07/01/22 End: 07/31/25 Due: 07/31/26

Glioma Patients Registry Based on Radiological, Histopathological and Genetic Analysis

Phase: N/A Priority: Normal
NCT ID: NCT04220424 Org: User:
Start: 11/01/18 End: 03/01/22 Due: 03/01/23

Randomized Trial of Glutathione with Anti-PD-1 and Chemotherapy in Advanced NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06896422 Org: User:
Start: 03/21/25 End: 12/31/27 Due: 12/31/28

A Study of Perioperative Camrelizumab Combined With Chemotherapy in Patients With Resectable ESCC

Phase: N/A Priority: Normal
NCT ID: NCT05182944 Org: User:
Start: 01/15/22 End: 01/15/27 Due: 01/15/28

MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence

Phase: N/A Priority: Normal
NCT ID: NCT04217018 Org: User:
Start: 01/01/17 End: 06/01/27 Due: 06/01/28

Study of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy

Phase: N/A Priority: Normal
NCT ID: NCT05350917 Org: User:
Start: 06/20/22 End: 06/20/26 Due: 06/20/27

A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

Phase: N/A Priority: Normal
NCT ID: NCT05231850 Org: User:
Start: 03/01/22 End: 09/01/27 Due: 09/01/28

Angiogenesis Inhibitor Plus Anti-PD-1/PD-L1 Antibody in Advanced Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05349045 Org: User:
Start: 05/05/22 End: 05/05/25 Due: 05/05/26

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06341530 Org: User:
Start: 01/31/24 End: 12/31/25 Due: 12/31/26

The Effectiveness of Endometrial Injury in IVF

Phase: N/A Priority: Normal
NCT ID: NCT02409745 Org: User:
Start: 02/28/15 End: 02/29/16 Due: 02/28/17

Newborns From Patients Treated With ART (Assisted Reproductive Technology)

Phase: N/A Priority: Normal
NCT ID: NCT03993158 Org: User:
Start: 01/01/10 End: 12/31/50 Due: 12/31/51

A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL

Phase: N/A Priority: Normal
NCT ID: NCT06564493 Org: User:
Start: 03/01/25 End: 12/31/29 Due: 12/31/30

In Vitro Activation of Dormant Follicles for Patients with Primary Ovarian Insufficiency

Phase: N/A Priority: Normal
NCT ID: NCT02322060 Org: User:
Start: 09/30/14 End: 10/31/21 Due: 10/31/22